C
C. Michel Zwaan
Researcher at Erasmus University Rotterdam
Publications - 52
Citations - 2395
C. Michel Zwaan is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 21, co-authored 52 publications receiving 1829 citations. Previous affiliations of C. Michel Zwaan include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
Kimmo Porkka,Perttu Koskenvesa,Tuija Lundán,Johanna Rimpiläinen,Satu Mustjoki,Richard Smykla,Robert A. Wild,Roger Luo,Montserrat Arnan,Benoit Brethon,Lydia Eccersley,Henrik Hjorth-Hansen,Martin Höglund,Hana Klamova,Håvar Knutsen,Suhag Parikh,Emmanuel Raffoux,Franz Gruber,Finella Brito-Babapulle,Hervé Dombret,Rafael F. Duarte,Erkki Elonen,Ron Paquette,C. Michel Zwaan,Francis Y. Lee +24 more
TL;DR: Dasatinib has promising therapeutic potential in managing intracranial leukemic disease and substantial clinical activity in patients who experience CNS relapse while on imatinib therapy.
Journal ArticleDOI
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
C. Michel Zwaan,Edward A. Kolb,Dirk Reinhardt,Jonas Abrahamsson,Souichi Adachi,Richard Aplenc,Eveline S. J. M. de Bont,Barbara De Moerloose,Michael Dworzak,Brenda Gibson,Henrik Hasle,Guy Leverger,Franco Locatelli,Christine Ragu,Raul C. Ribeiro,Carmelo Rizzari,Jeffrey E. Rubnitz,Owen P. Smith,Lillian Sung,Daisuke Tomizawa,Marry M. van den Heuvel-Eibrink,Ursula Creutzig,Gertjan J.L. Kaspers +22 more
TL;DR: The future is bright, with a wide range of emerging innovative therapies and with more and more international collaboration that ultimately aim to cure all children with AML, with fewer adverse effects and without late effects.
Journal ArticleDOI
The genetic basis and cell of origin of mixed phenotype acute leukaemia
Thomas B. Alexander,Thomas B. Alexander,Zhaohui Gu,Ilaria Iacobucci,Kirsten Dickerson,John K. Choi,Beisi Xu,Debbie Payne-Turner,Hiroki Yoshihara,Mignon L. Loh,John T. Horan,Barbara Buldini,Giuseppe Basso,Sarah Elitzur,Valerie de Haas,C. Michel Zwaan,Allen Eng Juh Yeoh,Dirk Reinhardt,Daisuke Tomizawa,Nobutaka Kiyokawa,Tim Lammens,Barbara De Moerloose,Daniel Catchpoole,Hiroki Hori,Anthony V. Moorman,Andrew S. Moore,Ondrej Hrusak,Soheil Meshinchi,Soheil Meshinchi,Etan Orgel,Meenakshi Devidas,Michael J. Borowitz,Brent L. Wood,Nyla A. Heerema,Andrew Carrol,Yung-Li Yang,Malcolm A. Smith,Tanja M. Davidsen,Leandro C. Hermida,Patee Gesuwan,Marco A. Marra,Yussanne Ma,Andrew J. Mungall,Richard A. Moore,Steven J.M. Jones,Marcus B. Valentine,Laura J. Janke,Jeffrey E. Rubnitz,Ching-Hon Pui,Liang Ding,Yu Liu,Jinghui Zhang,Kim E. Nichols,James R. Downing,Xueyuan Cao,Lei Shi,Stanley Pounds,Scott Newman,Deqing Pei,Jaime M. Guidry Auvil,Daniela S. Gerhard,Stephen P. Hunger,Hiroto Inaba,Charles G. Mullighan +63 more
TL;DR: A large-scale genomics study shows that the cell of origin and founding mutations determine disease subtype and lead to the expression of multiple haematopoietic lineage-defining antigens in mixed phenotype acute leukaemia.
Journal ArticleDOI
Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis
Julia Skokowa,Doris Steinemann,Jenny E. Katsman-Kuipers,Cornelia Zeidler,Olga Klimenkova,Maksim Klimiankou,Murat Ünalan,Siarhei Kandabarau,Vahagn Makaryan,Renée Beekman,Kira Behrens,Carol Stocking,Julia C. Obenauer,Julia C. Obenauer,Susanne Schnittger,Alexander Kohlmann,Marijke Valkhof,Remco Hoogenboezem,Gudrun Göhring,Dirk Reinhardt,Brigitte Schlegelberger,Martin Stanulla,Peter Vandenberghe,Jean Donadieu,C. Michel Zwaan,Ivo P. Touw,Marry M. van den Heuvel-Eibrink,David C. Dale,Karl Welte +28 more
TL;DR: The high frequency of cooperating RUNX1 and CSF3R mutations in CN patients suggests a novel molecular pathway of leukemogenesis: mutations in the hematopoietic cytokine receptor (G-CSFR) in combination with the second mutations in-situ in the downstream hematopolietic transcription fator (RUNX1).
Journal ArticleDOI
Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia
Brian V. Balgobind,Iris H.I.M. Hollink,Susan T.C.J.M. Arentsen-Peters,Martin Zimmermann,Jochen Harbott,H. Berna Beverloo,Anne R. M. von Bergh,Jacqueline Cloos,Gertjan J.L. Kaspers,Valerie de Haas,Zuzana Zemanova,Jan Stary,Jean-Michel Cayuela,André Baruchel,Ursula Creutzig,Dirk Reinhardt,Rob Pieters,C. Michel Zwaan,Marry M. van den Heuvel-Eibrink +18 more
TL;DR: Integrative analysis of type-I and type-II aberrations provides an insight into the frequencies, non-random associations and prognostic impact of the various aberration, reflecting the heterogeneity of pediatric acute myeloid leukemia.